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Background: Irritable bowel syndrome (IBS) is reported by one in ten of the population accounting for up to 40%
of new referrals to gastroenterology outpatients. Patients characteristically have abdominal discomfort and
disturbed bowel habit. Diarrhoea-predominant IBS is characterised by frequent loose stools with associated urgency
and abdominal cramps. Current symptomatic treatments can reduce bowel frequency but often fail to reduce
discomfort.
Mesalazine is an anti-inflammatory drug used to treat patients with inflammatory bowel disease. There is one pilot
study suggesting it may be beneficial to patients who have diarrhoea-predominant IBS but these findings need to
be confirmed in a larger trial. The current study aims to test the effectiveness of mesalazine to reduce symptoms in
diarrhoea-predominant IBS patients. The study will also investigate the mode of action of the drug, especially its
impact on mast cell activation.
Methods/design: This is a multicentre randomised, double-blind, placebo-controlled trial using a parallel group
design. At least 108 participants with diarrhoea-predominant IBS will be recruited through at least six hospitals. The
intervention is a 12-week course of 2g mesalazine granules taken up to twice a day. The comparator is a blinded
placebo granule formulation.
Outcome measures include stool diaries, symptom questionnaires, stool and blood samples together with rectal
mucosal biopsies. The daily stool diary will record stool frequency and form, urgency, bloating, abdominal pain and
a global satisfaction with control of IBS scored each week. The questionnaires will assess bowel symptoms, while
the samples and biopsies will be used to analyse underlying mechanisms of any response.
Primary outcome will be the average stool frequency during weeks 11 and 12 of the treatment period and will be
compared between treatment arms using an analysis of covariance in the form of a general linear model
incorporating baseline characteristics that are thought a priori to strongly predict outcome. The primary efficacy
parameter will be the difference in mean frequency between treatment arms.
Discussion: This report describes a randomised controlled trial that will provide evidence of any benefit of treating
diarrhoea-predominant IBS patients with mesalazine. The results will be available toward the end of 2013.
Trial registration: ISRCTN76612274
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While the presenting complaints in IBS are usually abdom-
inal pain and erratic bowel habits, at least half the IBS
patients have an associated history of anxiety or depression
and the presence of multiple unexplained physical symp-
toms otherwise known as ‘physical symptom disorder’ [1].
Patients often believe that stress aggravates their symptoms
but there is a poor correlation between stress and symp-
toms on a day-to-day basis [2].
Evidence is accumulating that activation of mast cells
can occur in stressed humans [3]. In diarrhoea-
predominant irritable bowel syndrome (IBS-D) patients,
mast cell numbers have been shown to be increased
[4-7]. We propose that anxiety and chronic stressors in-
crease the number of activated mast cells throughout
the gut in IBS patients, thereby inducing the characteris-
tic visceral hypersensitivity and abdominal pain. We
hypothesise that mesalazine treatment, through its anti-
inflammatory effects, will reduce the number of mast
cells and, thereby, reduce abdominal pain and diarrhoea.
Older studies using cromoglycate, a mast cell stabiliser
suggested benefit in those with evidence of allergy on
skin prick testing but these studies were uncontrolled
[8]. More recently there have been other smaller studies
targeting mast cells with antihistamines such as ketotifen
[9]. Although this reduced visceral hypersensitivity, it
had no effect on mast cell numbers or release of mast
cell mediators. Our own trial of prednisolone in post in-
fective IBS showed no benefit for IBS symptoms but was
of limited duration at just three weeks. It did however
show a fall in mast cell numbers in patients on prednis-
olone compared to patients on placebo, but the differ-
ence was not significant probably because the study was
underpowered [10]. A strategy that reduces mast cell
numbers over the long term might well be more effect-
ive than specific inhibitors of mast cell activation or in-
deed any specific mast cell products since these are
numerous, all with quite variable modes of action.
The first open-label trial of 12 patients with IBS-D
who responded to mesalazine [7] showed a benefit that
took about two to three months to become apparent.
There have since been three further reports of open-
label treatment [11,12] and two small randomised con-
trol trials [13,14]. All except the Corinaldesi trial [13]
used patients with IBS-D. The Bafutto trial showed a
reduction in stool frequency, stool consistency and ab-
dominal pain but was uncontrolled [12]. The Andrews
study involved just six patients but this showed that
mesalazine decreased biopsy proteolytic activity. The
Corinaldesi trial in unselected IBS patients showed a sig-
nificant reduction of mast cell numbers, an overall
reduction in inflammatory cells [13], and an improve-
ment in general well being without altering bowel func-
tion significantly.Rationale for the current study
Studies in Nottingham over the last decade demon-
strated the importance of anxiety and depression [15],
which along with adverse life events, increase the risk of
post-infective IBS (PI-IBS) [16]. The changes observed
in PI-IBS are very similar to those in IBS-D, the predom-
inant bowel disturbance being diarrhoea with a similar
prognosis [17]. This work has been supported by others
who have shown inflammatory changes in IBS-D
patients who do not have a background of previous in-
fection [18,19]. Increased gut permeability has also been
shown in IBS-D [20], a feature thought to be the result
of psychological stress and/or inflammation secondary
to infection [21].
We hypothesise that, through its anti-inflammatory
effects, mesalazine treatment will reduce abdominal pain
and diarrhoea by reducing the number of mast cells and
subsequent release of their mediators which increase gut
permeability and sensitivity [22]. Mesalazine therefore,
both by virtue of inhibiting other inflammatory pathways
and by directly inhibiting mast cell pathways, may re-
duce mucosal immune activation. We plan to investigate
the effect of long-term mesalazine on mast cell numbers,
the chronic inflammatory cells, and the mucosal produc-
tion of inflammatory cytokines IL-1β and TNF-α, as well
as the mast cell enzyme tryptase.
Methods/design
Trial purpose
The purpose of the trial is to define the clinical benefit
and possible mediators of the benefit of mesalazine in
IBS with diarrhoea.
We will therefore evaluate symptoms (primarily bowel
frequency) and markers reflecting mast cell activation
and small bowel tone.Trial design
This is a multicentre, two-arm, parallel group, double-
blind, randomised placebo- controlled trial comparing
mesalazine with placebo in patients with diarrhoea-
predominant irritable bowel syndrome. Trial consists of
a screening visit to check initial eligibility and to take
consent prior to the participant completing a two-week
screening phase stool diary. If they continue to remain
eligible they will be randomised to receive 12 weeks of
active or placebo treatment, stratified by site. Both
groups continue completing the stool diary during treat-
ment and will have three telephone contacts and two
visits prior to completion. Participants will be in the
study for 14 weeks. Please see Figure 1 for more details.
Trial objectives
The trial objectives were as follows:
Trial Treatment
0            1      2   3          4      Visits
(EOT)
SP 6 weeks6 weeks
-2 0 1 3 6 9 12 T (Weeks)
Diary Completion
Figure 1 Participant involvement.
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2) To assess the effect of mesalazine on
• Overall IBS symptoms
• Mast cell numbers, mucosal lymphocytes and faecal
tryptase activity
• Release of mast cell mediators from rectal biopsies.
• Small bowel tone by measurement of fasting small
bowel water content using magnetic resonance
imaging (MRI).
•To assess ability of biomarkers (mucosal/MRI
parameters) to predict treatment responseParticipant recruitment
Ethical approval for the study was obtained from
the Oxfordshire Research Ethics Committee B, United
Kingdom.
Participants were recruited from IBS clinics at the
investigator’s hospital, or from lists of patients who have
previously taken part in research studies and have indi-
cated that they would like to be contacted about future
relevant research projects. In addition, in conjunction
with the local Primary Care Research Network, we
approached general practitioners (GPs) to ask them to
search their databases for eligible participants and send
out letters of invitation along with a participant informa-
tion sheet (PIS). Either way, the initial approach was
from a member of the patient’s usual care team or from
appropriately authorised research nurses. We also adver-
tised in the local newspaper and information about the
study was also displayed in the relevant clinical areas.
Ethical approval was obtained for all advertisements or
posters displayed.
Patients were eligible for the study if they provided
written informed consent and if they: 1) were male or
female patients aged 18 to 75 years; 2) had had a colon-
oscopy or sigmoidoscopy within the last 12 months to
exclude microscopic or any inflammatory colitis. (If not,
but they have had a negative colonoscopy within fiveyears and symptoms are unchanged, then a sigmoidos-
copy and mucosal biopsy of the left colon was deemed
to be sufficient to exclude microscopic or any inflamma-
tory colitis); 3) met Rome III criteria for IBS-D prior to
screening phase; 4) had ≥25% soft (Bristol Stool Form
Score [BSFS] score >4) and <25% hard (BSFS 1 or 2)
stools during the screening phase, as indicated in the
daily symptom and stool diary; 5) had a stool frequency
of three or more per day for two or more days per week
during the screening phase; 6) had satisfactorily com-
pleted the daily stool and symptom diary during the
screening phase at the discretion of the investigator; and
7) if female and of child-bearing potential, willing and
able to use at least one highly effective contraceptive
method throughout the study. If (4) and/or (5) is/are not
met but the results are considered atypical (as observed
from medical history and patient recall) then the patient
can be rescreen on one occasion only.
Rome III criteria for IBS-D [23] were used to evaluate
effect of mesalazine on patients during course of study.
These criteria are as follows:
Abdominal Pain or discomfort at least two to three
days/month in the last three months (criterion fulfilled
for the last three months with symptom onset at least
six months prior to screening) associated with two or
more of the following:
1) Improvement with defecation;
2) Onset associated with a change of stool frequency;
3) Onset associated with a change in form (appearance)
of stool.
Patients were not eligible for the study if they: 1) were
pregnant or breast feeding; 2) had prior abdominal sur-
gery which may cause bowel symptoms similar to IBS
(note appendectomy and cholecystectomy will not be an
exclusion); 3) were unable to stop anti-muscarinics, anti-
spasmodics, high-dose tricyclic antidepressants (that is,
above 50 mg/day), opiates/anti-diarrhoeal drugs, NS-
AIDs (occasional over the counter use and topical for-
mulations were allowed), long-term antibiotics, other
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were on selective serotonin re-uptake inhibitors and
low-dose tricyclic antidepressants (that is, up to 50 mg/
day) for at least three months previous and unwilling to
remain on a stable dose for the duration of the trial; 5)
had other gastro-intestinal diseases including colitis and
Crohn’s disease; 6) had renal impairment, severe hepatic
impairment or salicylate hypersensitivity; 7) were cur-
rently participating in another trial or had been in a trial
within the previous three months; 8) in the opinion of
the investigator were considered unsuitable due to
inability to comply with instructions or 9) had serious
concomitant diseases (for example, cardiovascular, respi-
ratory, neurological et cetera).
Regarding (3) loperamide was allowed as a rescue
medication throughout the trial, however if more than
two doses/week were taken during the screening phase
then the patients became ineligible, though they could
be re-screened on one occasion only.The interventions
Mesalazine and placebo
A licensed mesalazine slow-release granule formulation
(2g) was used (PENTASAW, Ferring Pharmaceuticals
Ltd, West Drayton, United Kingdom.) A matching pla-
cebo granule formulation was also used. In order to main-
tain blinding, active and placebo granules were packaged
in matching de-identified trial-specific foil sachets.
The trial dose was 2g once a day (one dose in the
morning) for the first week of treatment, then, if the ini-
tial dose was tolerated, a step increase to 2g twice a day
(one dose in the morning, one dose in the evening) for
the remaining 11 weeks of treatment. If the current dose
was not tolerated participants could reduce that dose or
stop completely.
All dose adjustments were made in consultation with
the local investigator. Compliance was recorded in the
daily stool diary and from returned sachets.Randomisation and blinding
This was a double-blind study. Neither participant nor
supervising doctor nor study nurse was aware of the
treatment allocation.
Randomisation was based on a computer-generated
pseudo-random code using random permuted bal-
anced blocks of randomly varying size, created by
the Nottingham Clinical Trials Unit (NCTU). The
randomization was stratified by site with participants
randomly allocated (1:1 ratio) to either mesalazine or
placebo. Access to the master sequence of treatment
allocations was confined to the NCTU IT Manager
and the Nottingham University Hospitals NHS Trust
Clinical Trials pharmacy.Investigators/sites accessed the treatment allocation
for each participant by means of a remote, secure,
internet-based randomisation system developed and
maintained by the NCTU. The sequence of treat-
ment allocations was concealed until interventions
had all been assigned and recruitment, data collec-
tion, and all other trial-related assessments were
complete.
In the event of the need to break the code, usually
due to clinical need, the date and reason for break-
ing the code were recorded in the eCRF. The code
could only be broken by authorised personnel via
the web-based eCRF or, in the event the system
being inaccessible, the Nottingham University Hospi-
tals NHS Trust Clinical Trials pharmacy kept a copy
of the treatment allocations.
Primary endpoint
Clinical endpoint
1) Difference in average stool frequency during weeks
11–12 of the treatment period.
Mechanistic endpoint
1) Difference in mast cell numbers per mm2 during
weeks 11–12 of the treatment period.
Secondary endpoint
Clinical secondary endpoints during weeks 11 and 12 of
the treatment period:
1) Average daily severity of abdominal pain on a 0 to 10
scale.
2) Days with urgency.
3) Mean stool consistency using Bristol Stool Form
Score.
4) Global satisfaction with control of IBS symptoms as
assessed from the answer to the question ‘Have you
had satisfactory relief of your IBS symptoms this
week? Yes/No.’
Mechanistic secondary endpoints during weeks 11 and
12 of the treatment period:
1) Mast cell tryptase release during 6-hour biopsy
incubation
2) IL-1β, TNF-α, histamine and serotonin secretion
during same incubation
3) Small bowel tone assessed by volume of fasting small
bowel water
4) Fecal tryptase activity
5) Difference in primary outcome measure between
those with different TNFSF15 polymorphism
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of the treatment period:
1) EuroQol-5D (EQ-5D)
2) Centers for Disease Control and Prevention Health-
Related Quality of Life (CDC HRQOL4)
3) Hospital, Anxiety and Depression Scale (HADS)
4) Patient Health Questionnaire-15 (PHQ-15)Outcome measures
Daily symptom and stool diary
Participants completed a daily symptom and stool diary
throughout their participation indicating hours of pain,
severity of abdominal pain on a 0 to 10 scale, presence
of urgency (yes/no) and bloating on a 0–10 scale. They
were also asked on a weekly basis the following yes/no
question: ‘Have you had satisfactory relief of your IBS
symptoms this week?’IBS-D sub-groups
The Rome III criteria questionnaire will be used to as-
sess whether the participant has IBS-D. In addition the
participants will answer supplementary questions to
identify any cases that are post-infectious IBS-D.Psychological profiles
We used the HADS and PHQ-15 questionnaires, col-
lected at baseline and 12 weeks.Quality of life questionnaires
Quality of Life was assessed using the two generic qual-
ity of life measures that had been validated in IBS pa-
tient groups: the CDC HRQOL4 [24] and the EQ-5D
[25], which has been shown to be sensitive to a success-
ful treatment of symptoms [26].MRI (Nottingham only)
Fasting small bowel water content was assessed using
our previously validated MRI technique [27]. The vol-
ume of small bowel water gives an indirect assessment
of intestinal tone. We have previously shown that small
bowel water content is significantly reduced in IBS-D,
both fasting and postprandial [28].Flexible Sigmoidoscopy and biopsies (Nottingham only
Patients will undergo an unsedated flexible sigmoidos-
copy with biopsy of the sigmoid colon. Biopsies will be
taken to investigate mast cells, mRNA for IL-1, TNF-α
and protein levels, as well as for tryptase, serotonin and
histamine release on incubation of mucosal biopsies.Stool sample
Stool samples will be analysed for proteases and other in-
flammation biomarkers. Bacterial DNA isolated from stool
samples will also be analysed using the HITChip [29].
Blood sample
Serum isolated from blood samples were analysed for
inflammation biomarkers. DNA isolated from blood
samples were analysed for any genetic link between
polymorphisms and treatment response.
Sample size
Our previous study on diarrhoea-predominant IBS
patients gives a mean stool frequency of 3.1 (standard
deviation 2.0). Tuteja and colleagues reported mesala-
zine decreasing stool frequency by 1.4 bowel movements
per day [14]. We calculated from these data that 108
completed patients (randomized 1:1 to mesalazine or
placebo) would give the study an 80% power to detect
such an effect at the 1% significance level (90% at 5%
significance). As we had not accounted for attrition if
participants withdrew, these participants were replaced
in order to ensure 108 completed participants.
Much smaller numbers would be needed to assess the
effect of mesalazine on mast cell numbers and tryptase
release. Corinaldesi et al. reported a 36% decrease in
mast cell numbers from mean 9.2 (standard deviation
2.5) [13], which would have required just 12 patients to
show such a decrease with a power of 90% at the 1% sig-
nificance level.
Statistical analysis
The primary analysis will be performed on the full ana-
lysis set (that is, all randomised participants for whom
the primary endpoint (symptoms at 11 and 12 weeks) is
available) using an analysis of covariance in the form of
a general linear model incorporating terms for baseline
frequency, treatment arm, centre, and other baseline
characteristics which are thought a priori to strongly
predict outcome.
Secondary and mechanistic endpoints were treated
similarly, after transformation to approximate normality
as required for continuous variables, while binary and
count outcomes were handled by logistic or Poisson re-
gression, as appropriate. All analyses were performed
using the current version of STATA (StataCorp, Texas,
USA), adopting the intention to treat principle following
multiple imputation for missing data (with a sensitivity
analysis for the missing at random assumption for the
primary outcome). For mechanistic variables a per-
protocol analysis was additionally performed.
No interim or subgroup analyses were planned for
efficacy.
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the assessment of efficacy except that the safety set (that
is, all randomised participants who receive at least one
dose of the study drug) were used.
Procedures for missing, unused and spurious data
were handled by multiple imputation using the method
of chained equations.
Assessment of adverse events
This trial is using a drug, mesalazine, for which the side-
effect profile is well established. Therefore the study specific
definition of an adverse event was:
1) any study drug-related event as listed as a known
side effects of mesalazine with the exception of
diarrhoea and abdominal pain, which will only be
recorded if these disease symptoms are exacerbated.
OR
2) any condition detected or diagnosed after the
medicinal product has been administered and has a
possible, probable or definite causal relationship with
the study drug.
Due to the study specific definition the recording of
adverse events and serious adverse event reporting
began following the 1st dose of study treatment.
Definition of a protocol deviation
The following were predefined protocol violations with a
direct bearing on the primary endpoint:
1) Taking of rescue medication (loperamide) during the
primary endpoint assessment period (that is, weeks
11 and 12 of the treatment period).
2) Taking of antibiotics during the primary endpoint
assessment period (that is, weeks 11and 12 of the
treatment period).
This summary paper was based on protocol version
3.0, 5th May 2011. A copy of the full protocol is avai-
lable on request.
Trial status
Recruitment started in March 2011 and is anticipated to
continue until May 2013.
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